We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson Files Citizen Petition to Fend Off Generics of Rapaflo
Watson Files Citizen Petition to Fend Off Generics of Rapaflo
May 31, 2013
With marketing exclusivity for its enlarged prostate treatment Rapaflo ending in October, Watson Laboratories has filed a citizen petition with the FDA asking it to refuse a Paragraph IV ANDA submitted by Sandoz, which holds a patent for the preparation of the active ingredient.